PARP Inhibitor for Improving PROs in Ovarian Cancer

Submitted by admin5 on Mon, 09/18/2017 - 15:11

Which PARP inhibitor was recently found to increase quality of life in patients with ovarian cancer?


A. Rucaparib

B. Olaparib

C. Niraparib

D. Veliparib


Niraparib as a maintenance therapy can successfully contribute to sustained quality of life in recurrent ovarian cancer after a initial response to platinum-based chemotherapy. Read more about the study here.